” “

Contact Us

To be contacted by a sales representative or to receive updates when new information becomes available, please fill out the form below and provide us with your preferred contact information.

Please select at least one of the options below.

I’d like a Chiesi representative to contact me to answer a specific question I have about KENGREAL^® (cangrelor).

By checking this box, I give Chiesi USA, Inc. the right to store my personal data to respond to my request and confirm that I have read and agree to the terms of the Privacy Policy.

I’d like to receive email updates about KENGREAL.

By checking this box, I give Chiesi USA, Inc. permission to store my personal data and use that information to send me emails with information and updates on KENGREAL and confirm that I have read and agree to the terms of the Privacy Policy.

All fields are required unless otherwise indicated.

Title (optional)

First Name

Last Name

Email Address

ZIP Code

Medical Information

To request specific medical information about KENGREAL or to report adverse events or product complaints, contact the Medical Information Department.

Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-10881-800-FDA-1088.

Email:
US.Medical@chiesi.com

Phone:
1-888-661-92601-888-661-9260

Fax:
1-866-443-3092

Mail:
Chiesi USA, Inc.
175 Regency Woods Place
Suite 600
Cary, NC 27518

CONTACT CHIESI USA, INC.

Email:
kengreal@chiesi.com

Phone:
1-866-466-65031-866-466-6503

Important Safety Information

KENGREAL^® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL^® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y₁₂ function, including KENGREAL^®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL^® than with clopidogrel. Bleeding complications with KENGREAL^® were consistent across a variety of clinically important subgroups. Once KENGREAL^® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Indication

KENGREAL^® (cangrelor) for Injection is a P2Y₁₂ platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y₁₂ platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Please see Full Prescribing Information.